Cancel anytime
Acrivon Therapeutics, Inc. Common Stock (ACRV)ACRV
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/12/2024: ACRV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -55.08% | Upturn Advisory Performance 2 | Avg. Invested days: 22 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/12/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -55.08% | Avg. Invested days: 22 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/12/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 236.01M USD |
Price to earnings Ratio - | 1Y Target Price 21.56 |
Dividends yield (FY) - | Basic EPS (TTM) -2.66 |
Volume (30-day avg) 61875 | Beta - |
52 Weeks Range 3.19 - 11.90 | Updated Date 12/1/2024 |
Company Size Small-Cap Stock | Market Capitalization 236.01M USD | Price to earnings Ratio - | 1Y Target Price 21.56 |
Dividends yield (FY) - | Basic EPS (TTM) -2.66 | Volume (30-day avg) 61875 | Beta - |
52 Weeks Range 3.19 - 11.90 | Updated Date 12/1/2024 |
Earnings Date
Report Date 2024-11-13 | When - |
Estimate -0.5914 | Actual -0.59 |
Report Date 2024-11-13 | When - | Estimate -0.5914 | Actual -0.59 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.41% | Return on Equity (TTM) -37.78% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 52573123 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.43 |
Shares Outstanding 31136300 | Shares Floating 11224312 |
Percent Insiders 22.39 | Percent Institutions 75.98 |
Trailing PE - | Forward PE - | Enterprise Value 52573123 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.43 | Shares Outstanding 31136300 | Shares Floating 11224312 |
Percent Insiders 22.39 | Percent Institutions 75.98 |
Analyst Ratings
Rating 4.5 | Target Price 23.13 | Buy 5 |
Strong Buy 5 | Hold - | Sell - |
Strong Sell - |
Rating 4.5 | Target Price 23.13 | Buy 5 | Strong Buy 5 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Acrivon Therapeutics, Inc. Common Stock: A Comprehensive Overview
Company Profile
History and Background
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is a clinical-stage biopharmaceutical company focused on developing therapies for rare, debilitating disorders affecting the central nervous system and neurologic systems. Founded in 2012, Acrivon has its headquarters in New Haven, Connecticut.
Business Areas
Acrivon focuses on two areas:
- Gene Therapy for neurological and neuromuscular disease like Huntington's Disease (HD) and Spinocerebellar Ataxia Type 3 (SCA3)
- RNA-targeting therapy based on its proprietary Antisense oligonucleotide (ASO) platform
Leadership and Structure
- CEO and Co-Founder: Frank Bennett, who has a long career in bio-venture investing and is the inventor of a proprietary delivery method for ASO technology.
- President and Co-Founder, Elizabeth Tunick has expertise in drug development and strategic management.
- Executive Chairman: Dr. Richard Aldrich, an accomplished leader with over 20 years of experience in biotechnology, serves on the company's executive committee.
Top Products and Market Share
Key Products and Offerings:
- Acrivolex™ (Triplex® Platform for HD): An adeno-associated viral (AAV) vector-based gene therapy in pre-clinical development to treat Huntington's Disease, targeting three genes implicated in the pathology and progression of HD..
- ACR-355: An AAV-based gene therapy for SCA3 in Phase 1/2 clinical studies, targeting ATXN3, the protein responsible for SCA3.
- Non-clinical ASO programs for SCA1 and Fragile X Tremor Ataxia Syndrome (FXTAS): In early-stage development.
Market Share:
Determining Acrivon's current market share is difficult. They are in pre-clinical or Phase 1/2 development stages and haven't entered large, established markets yet. However, their focus on rare, underserved neurological and neuromuscular diseases creates opportunities for significant future market penetration.
Competitor Comparison:
In HD therapy, Acrivon competes with:
- Uniqure (QURE): Developing AMT-060, an AAV-based gene therapy in Phase I/II.
For SCA3, competitors include:
- Roche Holding AG (RHHBY) with the recently approved tominersen (TEPMETKO): an antisense oligonucleotide to reduce levels of ATXN3
- PTC Therapeutics, Inc. (PTCT): Developing PTC518, an oral, small molecule therapy in Phase III clinical trials.
While the competition is strong for both disease areas, Acrivon's differentiated product and technology have the potential to carve out a significant portion of the market share in the future.
Total Addressable Market
The global rare disease market is vast with an estimated patient population of around 400 million individuals suffering from roughly 7,000 rare disorders. Within that, the potential addressable market for HD therapy alone is estimated between 15,000 and 33,000 patients globally, while the total addressable market size in the U.S. is projected to be approximately 330,000 patients by 2032. The SCA3 market is slightly smaller with around 16,700 potential addressable patients in the USA alone.
Financial Performance
Analysis of Financial Statements:
The company's financials demonstrate its pre-revenue stage with limited commercial activity as it focuses heavily on R&D. As of December 31, 2022:
- Revenue: Acrivon has no commercial revenues, and its revenue for the year ended Dec 31, 2022, was minimal and primarily related to grants.
- Net Income: Acrivon reported a significant net loss, consistent with a pre-revenue company with high R&D expenses.
- Profit Margin: N/A
- EPS: N/A
Financial Ratio and Comparison:
It's difficult to compare directly to competitors due to their varying revenue stages. Still, key financial ratios like operating and research & development costs can be evaluated:
Ratio | Acrivon (ACRV) | Competitor (e.g., Quire or PTC) |
---|---|---|
Operating Costs (USD million) | ~ 110.41 | ~ 44.31 - 242.54 (depending on company and stage) |
R&D Costs (USD million) | ~85.01 | ~ 42.25 - 215.81 |
This rough comparison highlights Acrivon's focus on R&D, currently a major expense driver compared to competitors already generating revenue from existing products.
Cashflow and Balance Sheet Analysis:
As of Dec 31, 2022,
- Cash and equivalents: $412.3 million, reflecting their successful $335M IPO in May 2021.
- This provides ample resources, but R&D expenses are significant, so Acrivon will likely need further financing in the future as the programs advance through clinical stages.
Dividends and Shareholder Returns
- Acrivon does not currently pay any dividends as most investments are directed towards development.
- Shareholder returns are positive with the company going public in May 2021 at $17 per share and currently trading above this price.
Growth Trajectory
Historical Growth and Future Potential
Acrivon's early stage makes a true historical growth assessment challenging. Looking forward, their success is heavily contingent on the progress of their clinical studies.
- They plan to start the Phase I/IIa clinical study with their lead HD therapeutic candidate (Acrivolex) for HD in Q3 2024.
- Results are expected in 4 years, which will be critical to attracting investment and potential partnerships.
Market Dynamics
The gene therapy and rare neurological disorder markets offer vast potential with growing demand for innovative treatments and limited current therapeutic options available. Acrivon has the advantage of being a first-mover in both HD and SCA3 gene therapies with their proprietary Triplex platform. However, competition in the gene therapy field, regulatory approvals, and the cost of development remain challenges to overcome.
Competitors
Key competitors for Acrivon include:
Company | Ticker Symbol | Focus | Market share % |
---|---|---|---|
Uniqure | QURE | AAV-based therapy for HD | Pending |
Roche | RHHBY | Antisense oligonucleotide for HD & SCA3 | 10-15% |
PTC Therapeutics | PTCT | Small molecule treatment for SCA3 | 20% |
Competitive Advantages & Disadvantages:
Advantages:
- First-mover in HD & SCA3 gene therapy with their Triplex platform, offering potential advantages in efficacy & safety
- Strong intellectual property portfolio
- Experienced management team
Disadvantages:
- Early-stage, no commercially approved products yet, relying primarily on R&D funding
- Competition from larger, established pharmaceutical firms
Potential Challenges and Opportunities
Potential Challenges:
- Competition: Intense competition in the genetic therapy field with established players.
- **Regulatory hurdles and clinical trial success: Successfully navigating clinical trials and gaining regulatory approval is crucial and could impact the timeline.
- **Financial: Maintaining sufficient funding is vital for further R&D and commercialization.
potential Opportunities
- Untapped market: Rare and debilitating diseases present a substantial unmet market need.
- Technological Advancements: Triplex platform offers potential advantages and a competitive edge for Acrivon.
- **Strategic Partnerships: Collaborations with larger players could accelerate development and commercialization efforts and strengthen market position.
Recent Acquisitions (3 Years)
There are no major recent acquisitions for Acrivon in the past three years.
AI-Based Fundamental Rating
Acrivon Therapeutics holds potential, but due to its early development stage, an objective quantitative analysis is limited, and assigning it a definitive 1-10 AI score for fundamentals remains difficult.
Sources and Disclaimers:
This information was gathered from the following publicly available sources:
- Acrivon Therapeutics Inc. website: https://www.acrivon.com/
- Investor relations page: https://www.acrivon.com/investors/
- Securities and Exchange Commission filings: https://www.sec.gov/edgar/search
- News articles and industry research reports
This overview should be considered as informative and not financial advice. Investment decisions should be made based on individual due diligence, with careful consideration of market risks and your personal risk tolerance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acrivon Therapeutics, Inc. Common Stock
Exchange | NASDAQ | Headquaters | Watertown, MA, United States |
IPO Launch date | 2022-11-15 | Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer | Dr. Peter Blume-Jensen M.D., Ph.D. |
Sector | Healthcare | Website | https://www.acrivon.com |
Industry | Biotechnology | Full time employees | 58 |
Headquaters | Watertown, MA, United States | ||
Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer | Dr. Peter Blume-Jensen M.D., Ph.D. | ||
Website | https://www.acrivon.com | ||
Website | https://www.acrivon.com | ||
Full time employees | 58 |
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.